Johnson & Johnson Statement on COVID-19 Vaccine (7/12)

NEW BRUNSWICK, N.J., July 12, 2021 – The safety and well-being of the people who use our products is our number one priority.

Rare cases of the neurological disorder, Guillain-Barré syndrome have been reported following vaccination with the Janssen COVID-19 vaccine. Most occurred within 42 days after vaccination. While the chance of having this occur is very low, Johnson & Johnson has updated its COVID-19 Vaccine Factsheet to include important information about these rare cases and on the signs and symptoms of Guillain-Barré syndrome. Updates with this new information will be implemented in other regions of the world according to local regulatory procedures.

Any adverse event report about individuals receiving Johnson & Johnson’s single-shot COVID-19 vaccine, as well as our own assessment of the report, is shared with the U.S. Food and Drug Administration, the European Medicines Agency, the World Health Organization and other health authorities around the world where our vaccine is authorized. We strongly support raising awareness of the signs and symptoms of rare events to ensure they can be quickly identified and effectively treated.

Evidence has demonstrated that Johnson & Johnson’s single-shot COVID-19 vaccine offers protection against COVID-19 disease and prevents hospitalization and death, including in countries where viral variants are highly prevalent. A single-shot vaccine that provides this level of protection represents an important tool in the global fight against COVID-19, as we strive to help end this deadly pandemic.

For further information on the safety of authorized COVID-19 vaccines, please visit: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html

[Statement updated 9:00pm ET]

What Is the Janssen COVID-19 Vaccine?

The Janssen COVID-19 Vaccine is an unapproved vaccine that may prevent COVID-19. There is no FDA-approved vaccine to prevent COVID-19.

The FDA has authorized the emergency use of the Janssen COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age and older under an Emergency Use Authorization (EUA).

IMPORTANT SAFETY INFORMATION

WHAT SHOULD YOU MENTION TO YOUR VACCINATION PROVIDER BEFORE YOU GET THE JANSSEN COVID-19 VACCINE?

Tell the vaccination provider about all of your medical conditions, including if you:

- have any allergies
- have a fever
- have a bleeding disorder or are on a blood thinner
- are immunocompromised or are on a medicine that affects your immune system
- are pregnant or plan to become pregnant
- are breastfeeding
- have received another COVID-19 vaccine
WHO SHOULD NOT GET THE JANSSEN COVID-19 VACCINE?
You should not get the Janssen COVID-19 Vaccine if you:

- had a severe allergic reaction to any ingredient of this vaccine.

HOW IS THE JANSSEN COVID-19 VACCINE GIVEN?
The Janssen COVID-19 Vaccine will be given to you as an injection into the muscle. The Janssen COVID-19 Vaccine vaccination schedule is a single dose.

WHAT ARE THE RISKS OF THE JANSSEN COVID-19 VACCINE?
Side effects that have been reported with the Janssen COVID-19 Vaccine include:

- Injection site reactions: pain, redness of the skin, and swelling.
- General side effects: headache, feeling very tired, muscle aches, nausea, fever.

Severe Allergic Reactions
There is a remote chance that the Janssen COVID-19 Vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the Janssen COVID-19 Vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received your vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include:

- Difficulty breathing
- Swelling of your face and throat
- A fast heartbeat
- A bad rash all over your body
- Dizziness and weakness

Blood Clots with Low Levels of Platelets
Blood clots involving blood vessels in the brain, lungs, abdomen, and legs along with low levels of platelets (blood cells that help your body stop bleeding), have occurred in some people who have received the Janssen COVID-19 Vaccine. In people who developed these blood clots and low levels of platelets, symptoms began approximately one to two weeks following vaccination. Reporting of these blood clots and low levels of platelets has been highest in females ages 18 through 49 years. The chance of having this occur is remote. You should seek medical attention right away if you have any of the following symptoms after receiving Janssen COVID-19 Vaccine:

- Shortness of breath,
- Chest pain,
- Leg swelling,
- Persistent abdominal pain,
- Severe or persistent headaches or blurred vision,
- Easy bruising or tiny blood spots under the skin beyond the site of the injection.

These may not be all the possible side effects of the Janssen COVID-19 Vaccine. Serious and unexpected effects may occur. The Janssen COVID-19 Vaccine is still being studied in clinical trials.

Guillain Barré Syndrome
Guillain Barré syndrome (a neurological disorder in which the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis) has occurred in some people who
have received the Janssen COVID-19 Vaccine. In most of these people, symptoms began within 42
days following receipt of the Janssen COVID-19 Vaccine. The chance of having this occur is very
low. You should seek medical attention right away if you develop any of the following symptoms after
receiving the Janssen COVID-19 Vaccine:

- Weakness or tingling sensations, especially in the legs or arms, that’s worsening and
  spreading to other parts of the body
- Difficulty walking
- Difficulty with facial movements, including speaking, chewing, or swallowing
- Double vision or inability to move eyes
- Difficulty with bladder control or bowel function

**WHAT SHOULD I DO ABOUT SIDE EFFECTS?**

If you experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital.

Call the vaccination provider or your healthcare provider if you have any side effects that bother you
or do not go away.

Report vaccine side effects to **FDA/CDC Vaccine Adverse Event Reporting System (VAERS).**

The VAERS toll-free number is 1-800-822-7967 or report online to
[https://vaers.hhs.gov/reportevent.html](https://vaers.hhs.gov/reportevent.html). Please include “Janssen COVID-19 Vaccine EUA” in the first
line of box #18 of the report form. In addition, you can report side effects to Janssen Biotech Inc. at
1-800-565-4008.

Please read Emergency Use Authorization (EUA) Fact Sheet for Recipients and Caregivers
questions you have with the vaccination provider.

**Cautions Concerning Forward-Looking Statements**

This media statement contains “forward-looking statements” as defined in the Private Securities
Litigation Reform Act of 1995 regarding development of a potential preventive vaccine for COVID-
19. The reader is cautioned not to rely on these forward-looking statements. These statements are
based on current expectations of future events. If underlying assumptions prove inaccurate or known
or unknown risks or uncertainties materialize, actual results could vary materially from the
expectations and projections of the Janssen Pharmaceutical Companies, and/or Johnson &
Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties
inherent in product research and development, including the uncertainty of clinical success and of
obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and
delays; competition, including technological advances, new products and patents attained by
competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or
regulatory action; changes in behavior and spending patterns of purchasers of health care products
and services; changes to applicable laws and regulations, including global health care reforms; and
trends toward health care cost containment. A further list and descriptions of these risks,
uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K
for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note
Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most
recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the
Securities and Exchange Commission. Copies of these filings are available online at [www.sec.gov](http://www.sec.gov),
[www.inj.com](http://www.inj.com) or on request from Johnson & Johnson. None of the Janssen Pharmaceutical
Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result
of new information or future events or developments.